MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy.
about
Structural genomics of protein phosphatasesCombined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndromeAdvances in Nuclear Magnetic Resonance for Drug Discovery.Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor.Mass spectrometry and non-covalent protein-ligand complexes: confirmation of binding sites and changes in tertiary structure.An ultraefficient affinity-based high-throughout screening process: application to bacterial cell wall biosynthesis enzyme MurF.Estimating protein-ligand binding affinity using high-throughput screening by NMR.Covalent modification of stathmin by CCNU determined by FTMS analysis of modified proteins and tryptic peptidesDevelopment of a screening assay for ligands to the estrogen receptor based on magnetic microparticles and LC-MS.Fragment-based drug discovery using the SHAPES method.Mapping the surface of Escherichia coli peptide deformylase by NMR with organic solvents.Beyond the paradigm: Combining mass spectrometry and nuclear magnetic resonance for metabolomics.Characterization of the allosteric inhibition of a protein-protein interaction by mass spectrometry.
P2860
Q27649211-2972FD91-39F1-4AF5-92CC-29C2E961F0EBQ28301617-5592114E-3449-44BD-BFB4-33997F3E168FQ30387229-A075D9DF-9811-4566-8581-296BD0745BC6Q30762192-F6655E10-8DFC-4A5A-A673-3B858EBE61D4Q30929214-2E4C0080-56F4-4DBB-B6A4-5764F8A851BDQ33257634-88CE3CD3-D7E4-4EA4-BF93-6D322720874CQ33373482-BB903AEC-A995-4354-BFC2-14115C4B88B4Q36492940-CE027BC0-4CC4-4FBC-9C22-28C62FE7D8A0Q37328982-EA1BFB3F-7BAC-4347-B214-14F0A64D6127Q38089130-CEF485DC-3A90-4312-B55E-3BD91BA8D2CFQ38270124-48F0BE08-B602-484E-81CE-05E318BEB657Q38759621-A3CAEAE4-C66C-465D-9909-C211A283CC05Q44263989-60DF27A9-4A24-4494-B743-D166B87DD5A9
P2860
MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@ast
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@en
type
label
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@ast
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@en
prefLabel
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@ast
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@en
P2093
P356
P1433
P1476
MS/NMR: a structure-based appr ...... gnetic resonance spectroscopy.
@en
P2093
P304
P356
10.1021/AC0006270
P407
P577
2001-02-01T00:00:00Z